South Dakota Board of Pharmacy Reminder Regarding Compounding

STAFF NOTES 
 As a result of the tragic events that occurred with the New England Compounding Center Pharmacy in Framingham, Massachusetts; it is imperative that anyone compounding Sterile Products should review their policies and procedures as it relates to the USP 797 document and ARSD 20:51:31 (Sterile Compounding Practices).  The Board encourages you to print off the current version of USP 797. USP is making the document available on a temporary basis by going to this link:  http://www.usp.org/usp-healthcare-professionals/compounding/compounding-general-chapters/download-usp-nf-general-chapter-pharmaceutical-compoundingIf you are outsourcing sterile compounded products, the Board would suggest that you visit the ASHP website (www.ashp.org) to review their Sterile Compounding Resource Center.  They provide guidelines on outsourcing sterile compounding services. It is essential for the safety of all patients that all the pharmacies that compound medications, regardless of setting, adhere to the very highest standards. 
Source found here

South Dakota Board of Pharmacy's Position Regarding Office Use

MEDICATION REQUESTS FOR “OFFICE USE”
The board receives frequent advice from pharmacists related to prescription the pharmacy may receive from a prescriber indicating the “for office use” on the prescription. SDCL 36-11-2 (22) defines this. “Prescription drug order,” a written or oral order of a practitioner for a drug or drug device for a specific patient. Therefore, a prescription that is not patient specific is not valid. If a practitioner requests medication from a pharmacy, this transaction is considered a wholesale distribution. For non-controlled substances, the invoice must contain the name, strength, and dosage form of the medication, date of the transaction, name and address of the seller and the purchaser. For controlled substances, the record must contain all the information stated above, as well as the DEA numbers of the both the seller and the purchaser. If the medication is a CII controlled substance, the purchaser must execute a DEA Form 222 to the seller prior to the transaction. Records for controlled substance transaction must be maintained in a readily retrievable manner for a minimum of 2 years.  

Office Use in South Dakota

Medication Requests for ‘Office Use’
The Board receives frequent advice from pharmacists
related to prescriptions the pharmacy may receive from a
prescriber indicating “for office use” on the prescription.
SDCL 36-11-2 (22) defines this. “Prescription drug order”
is a written or oral order of a practitioner for a drug or drug
device for a specific patient. Therefore, a prescription that
is not patient-specific is not valid. If a practitioner requests
medication from a pharmacy, this transaction is considered
a wholesale distribution. For non-controlled substances,
the invoice must contain the name, strength, and dosage
form of the medication, date of the transaction, and name
and address of the seller and the purchaser. For controlled
substances (CS), the record must contain all the information
stated above, as well as the Drug Enforcement Administration
(DEA) numbers of the both the seller and the purchaser.
If the medication is a Schedule II CS, the purchaser must
execute a DEA Form 222 to the seller prior to the transaction.
Records for CS transactions must be maintained in
a readily retrievable manner for a minimum of two years.

Source found in South Dakota Board of Pharmay Newsletter for January 2013 found here 

South Dakota Board of Pharmacy Compounding

From the South Dakota Board of Pharmacy Newletter for January 2013:

Staff Notes
As a result of the tragic events that occurred with the New England Compounding Center pharmacy in Framingham, MA, it is imperative that anyone compounding sterile products review their policies and procedures as it relates to the United States Pharmacopeia (USP) Chapter 797 document and ARSD 20:51:31 (Sterile Compounding Practices). The Board encourages you to print off the current version of USP Chapter 797. USP is making the document available free of charge on a temporary basis by visiting the following link: www.usp.org/usp-healthcare-professionals/
compounding/compounding-general-chapters/downloadusp-nf-general-chapter-pharmaceutical-compounding. If you are outsourcing sterile compounded products, the
Board would suggest that you visit the American Society of Health-System Pharmacists Web site (www.ashp.org) to review their Compounding Resource Center. They provide
guidelines on outsourcing sterile compounding services. It is essential for the safety of all patients that all the pharmacies that compound medications, regardless of setting, adhere to the very highest standards.

Source found here